Chávez, AndrésAndrésChávezEscobar, AngélicaAngélicaEscobarMoya, PabloPabloMoyaJens R. Wendland2025-08-252025-08-252019-11-1510.3389/fphar.2019.013622-s2.0-85075786430https://cris-uv-2.scimago.es/handle/123456789/3553WOS:000499883700001Obsessive compulsive disorder (OCD) is a heterogeneous psychiatric disorder affecting 1%-3% of the population worldwide. About half of OCD afflicted individuals do not respond to currently available pharmacotherapy, which is mainly based on serotonin reuptake inhibition. Therefore, there is a critical need to search novel and improved therapeutic targets to treat this devastating disorder. In recent years, accumulating evidence has supported the glutamatergic hypothesis of OCD, and particularly pointing a potential role for the neuronal glutamate transporter EAAT3. This mini-review summarizes recent findings regarding the neurobiological basis of OCD, with an emphasis on the glutamatergic neurotransmission and EAAT3 as a key player in OCD etiology.enacceso abiertoPharmacology And PharmacyPharmacologyreview